While targeting mTOR offers a promising approach for cancer therapy, there are several challenges. One major issue is the development of resistance to mTOR inhibitors. Cancer cells can activate alternative signaling pathways or undergo genetic mutations that render mTOR inhibitors less effective. Additionally, mTOR inhibition can lead to feedback activation of upstream pathways, potentially diminishing the therapeutic effect.
